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Abstract
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease with the need for
treatment optimization. Previously, high expression of Insulin-like growth factor binding protein 7 (IGFBP7), a
member of the IGF system, was identified as negative prognostic factor in adult T-ALL patients. Since aberrant
IGFBP7 expression was observed in a variety of neoplasia and was relevant for prognosis in T-ALL, we investigated
the functional role of IGFBP7 in Jurkat and Molt-4 cells as in vitro models for T-ALL.
Methods: Jurkat and Molt-4 cells were stably transfected with an IGFBP7 over-expression vector or the empty
vector as control. Proliferation of the cells was assessed by WST-1 assays and cell cycle status was measured by
flow-cytometry after BrDU/7-AAD staining. The effect of IGFBP7 over-expression on sensitivity to cytostatic drugs
was determined in AnnexinV/7-AAD assays. IGF1-R protein expression was measured by Western Blot and flow-
cytometric analysis. IGF1-R associated gene expression profiles were generated from microarray gene expression data
of 86 T-ALL patients from the Microarrays Innovations in Leukemia (MILE) multicenter study.
Results: IGFBP7-transfected Jurkat cells proliferated less, leading to a longer survival in a nutrient–limited environment.
Both IGFBP7-transfected Jurkat and Molt-4 cells showed an arrest in the G0/G1 cell cycle phase. Furthermore, Jurkat
IGFBP7-transfected cells were resistant to vincristine and asparaginase treatment. Surface expression and whole protein
measurement of IGF1-R protein expression showed a reduced abundance of the receptor after IGFBP7 transfection in
Jurkat cells. Interestingly, combination of the IGF1-R inhibitor NPV-AEW541 restored sensitivity to vincristine in IGFBP7-
transfected cells. Additionally, IGF1-R associated GEP revealed an up-regulation of important drivers of T-ALL
pathogenesis and regulators of chemo-resistance and apoptosis such as NOTCH1, BCL-2, PRKCI, and TP53.
Conclusion: This study revealed a proliferation inhibiting effect of IGFBP7 by G0/G1 arrest and a drug resistance-
inducing effect of IGFBP7 against vincristine and asparaginase in T-ALL. These results provide a model for the
previously observed association between high IGFBP7 expression and chemotherapy failure in T-ALL patients. Since the
resistance against vincristine was abolished by IGF1-R inhibition, IGFBP7 could serve as biomarker for patients who may
benefit from therapies including IGF1-R inhibitors in combination with chemotherapy.
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Background
Acute lymphoblastic leukemia (ALL) is a heterogeneous
disease which survival rate has greatly improved during
the last decades due to improvement in risk stratification
and adapted treatment strategies. Despite these advances,
adult T-cell acute lymphoblastic leukemia (T-ALL) pa-
tients only have a survival of 40–70 %, depending on
protocol and age group. Thus the urgent need for the de-
velopment of novel therapy approaches remains [1, 2].
Insulin-like growth factor binding protein 7 (IGFBP7)
is a part of the IGFBP family (IGFBP1-7) of proteins that
bind insulin-like growth factors (IGFs) to regulate their
bioavailability and transport. IGFs in turn bind to IGF-
receptor 1 (IGF1-R), which has a tyrosine-kinase domain
and acts through the PI3K-AKT and RAS-RAF-MAPK
pathways [3]. In addition, IGFBPs also have IGF-
independent actions but the respective molecular mech-
anism of cellular transduction have only been described
for some of them [4, 5]. For example IGFBP3 was re-
vealed to bind to a receptor and nuclear localization was
observed for IGFBP2, −3 and −5 [6–8].
IGFBP7 has been described as tumor suppressor in
several human cancers. In breast, colorectal and hepato-
cellular carcinoma patients down-regulation of IGFBP7
in tumor cells was associated with a worse prognosis
[9–11]. In hepatocellular carcinoma and malignant mel-
anoma IGFBP7 was even suggested as therapeutic agent
as it inhibited tumor cell viability and promoted apop-
tosis in vivo and in vitro [12–14].
In leukemia, IGFBP7 was reported to be co-expressed
with the negative prognostic factor brain and acute
leukemia, cytoplasmic (BAALC) in T-ALL and acute mye-
loid leukemia (AML) patients [15]. High IGFBP7 mRNA
expression was found to be associated with primary ther-
apy resistance and negative outcome in T-ALL patients
[15]. Similarly to findings of studies with different malig-
nant cell lines, addition of rIGFBP7 was able to decrease
proliferation of leukemic cell lines in vitro [12, 15–19].
Several studies have revealed a link between IGFBP7
and acute leukemia: in childhood AML and ALL IGFBP7
was found to be up-regulated and high expression was as-
sociated with lower survival in precursor B-cell Ph(−) ALL
patients [20, 21]. Also ALL blasts were found to be pro-
tected from asparaginase through IGFBP7 expression
induced by co-culture of the blasts with bone marrow
stroma cells (BMSC) [21].
However, further actions and downstream targets of
IGFBP7 in acute leukemia remain yet to be investigated.
Thus, in this study we explored IGFBP7’s functional role
in T-ALL and uncovered mechanisms of its actions
directing drug resistance. Our study revealed IGFBP7-
induced resistance against chemotherapeutic drugs in T-
ALL. Additionally our results underscore an interaction
of IGFBP7 and the IGF1-R.
Methods
Cell lines and culture
The human cell lines K562 (chronic myeloid leukemia;
ACC-10), Jurkat (T-ALL; ACC-282), Molt-4 (T-ALL;
ACC-362) and KG-1a (erythroleukemia; ACC-421) were
purchased from the DSMZ (Braunschweig, Germany).
Cells were maintained in RPMI1640 medium containing
25 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 100 U/mL penicillin and 100 mg/mL streptomycin
(all from Merck Millipore, Darmstadt, Germany). Medium
was supplemented with 10 % fetal bovine serum (20 % for
Molt-4 cells; Linaris, Bettingen, Germany). Cell cultures
were routinely checked for mycoplasma contamination
using PCR (Merck Millipore).
Plasmid constructs and transfection
Human cDNA prepared from normal BMSCs served
as template for a standard PCR (Life Technologies,
Regensburg, Germany) to amplify the IGFBP7 tran-
script variant1 (accession number: NCBI NM_001553.2)
using the primers 5’-CACCCCGCCATGGAG-3’ and
5’-TATAGCTCGGCACCTTCACC-3’. The 857 bp PCR
product was cloned into vector pcDNA3.1myc/HisC (Life
Technologies, Regensburg, Germany) for eukaryotic over-
expression (pIGFBP7). Jurkat and Molt-4 cells were trans-
fected with pIGFBP7 or the empty vector for as control
(pCntrl) using the Nucleofector device (Lonza, Basel,
Switzerland) according to the manufacturer’s instructions.
After 24 hours, transfected cells received neomycin
(800 μg/mL; Merck Millipore, Darmstadt, Germany) for
three weeks before IGFBP7 over-expression was con-
firmed by qRT-PCR. Cells were cloned by limiting dilution
into 96-well plates (Nunc, Glostrup, Denmark). Cultures
were kept in the presence of 800 μg/mL neomycin for an
additional 4 weeks. Before conductions of experiments,
cells were thawed, cultured for two weeks in the presence
of neomycin and stable IGFBP7 over-expression recon-
firmed by qRT-PCR.
RNA extraction and quantitative real-time PCR
RNA was isolated with the RNeasy Kit (Qiagen, Hilden,
Germany) and transcribed into cDNA using MMLV re-
verse transcriptase (Epicentre, Chicago, USA). Quantita-
tive real-time PCR (qRT-PCR) for IGFBP7 was performed
as previously described in a Sybr Green (Invitrogen
GmbH, Karlsruhe, Germany) PCR assay [22] using the
primers IGFBP7-forward: 5’-CATCACCCAGGTCAGCA
AG-3’ and IGFBP7-reverse: 5’-TCACAGCTCAAGTACA
CCTG-3’. To measure IGF1R mRNA expression primers
IGF1R-forward 5’-ACGGGGCGATCTCAAAAGTT-3’
and IGF1R-reverse 5’-CTCTCCGGCCATCTGAATCA-3’
were used. Expression of the house keeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used as
internal control. Relative Expression values were expressed
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as 2-ΔCT using the comparative cycle threshold (ct)
method [23].
ELISA
IGFBP7 as secreted protein is likely to act through
paracrine/autocrine pathways; therefore its concentra-
tion in the conditioned medium from IGFBP7 over-
expressing versus control cell lines was measured with
a “Super-X” IGFBP7-ELISA kit (Antigenix America Inc.,
NY, USA) along the manufacturer’s instructions. To
harvest conditioned medium, transfected cells were
seeded at 1×106 cells/ml and grown for four days.
The cells were then separated from the medium by
centrifugation for 10 min at 2000 rpm at 4 °C and
the medium was treated with cOmplete Mini protease
inhibitor cocktail (Roche, Basel, Switzerland) and stored at
−80 °C until analysis.
WST-1 proliferation assays
To determine the effect of IGFBP7 over-expression on
proliferation of leukemic cell lines, the pCntrl or pIGFBP7
transfected clones were seeded in triplicates in different
96-well plates for separate time points. 1×105 cells/well in
100 μl were seeded and incubated at 37 °C, 5 % CO2 for
one to four days. At the endpoint of the experiment, 10 μl
WST-1 reagent (Roche, Basel, Switzerland), diluted 1:2
with regular medium, was added to each well. Plates were
then incubated for two hours to allow for the reduction of
WST-1 reagent to soluble formazan by the respiratory
chain of the viable cells. Absorbance was measured with a
Sunrise (Tecan, Männedorf, Switzerland) microplate ab-
sorbance reader at 450 nm with a reference wavelength of
620 nm.
Apoptosis assays
Apoptosis of cells treated with drugs or starvation-induced
apoptosis was measured by staining for AnnexinV-
phycoerythrin (FITC) and 7-amino-actinomycin D (7-AAD)
using an AnnexinV–FITC apoptosis detection kit (BD
Pharmingen, Heidelberg, Germany). For chemosensitivity-
assays cells were seeded at 1×106 cells/ml in triplicates
and treated with vincristine (1 ng/ml), etoposide (1 μg/
ml), cytarabine (araC) (1 μg/mL) or asparginase (1 IU/ml)
in combination with DMSO alone or 500 nM IGF1-R-
inhibitor NVP-AEW541 (AEW451; Novartis AG, Basel,
Switzerland) dissolved in DMSO. Drug concentrations
used in the assays were determined in prior WST-1 assays
of different concentrations. Cells were harvested after
24 h and analyzed by FACSCalibur (BD Pharmingen,
Heidelberg, Germany).
BrDU cell cycle assays
Cell cycle analysis was performed using a BrDU-FITC
kit (BD Pharmingen, Heidelberg, Germany) as described
in manufacturer’s protocol. Before staining and FACS
analysis, cells were incubated with 10 μM BrDU for four
hours.
IGF1-R FACS staining
IGF1-R surface expression was measured by a flowcyto-
metric assay. Cells were seeded at 1×106 cells/ml in du-
plicates, cultured normally for four days and stained
with anti-IGF-IR antibody, clone αIR3 (Merck Millipore,
Darmstadt, Germany) which recognizes the ~130 kDa α
and the ~90 kDa β subunits of the IGF1-R. For isotype
controls an unspecific mouse IgG1 was used (Santa Cruz
Biotechnology, Dallas, USA). For FACS analysis samples
were stained with anti-mouse IgG Alexa®488 (New
England Biolabs, Ipswich, USA) as secondary antibody.
The median fluorescence intensity (MFI) of the sam-
ples was normalized to the MFI of the isotype controls
before pooling values of independent experiments.
Western blot
Cells were seeded at 1×106 cells/ml, incubated for two
days, and lysed in RIPA buffer [20 mM Tris–HCl,
150 mM NaCL, 1 mM NaCl, 1 mM Na2-EDTA, 1 mM
EGTA, 1 % NP-40, 1 % sodium deoxycholate, 2.5 mM so-
dium pyrophosphate, 1 mM b-glycerophosphate, 1 mM
Na3VO4 and cOmplete Mini protease inhibitor cocktail
(Roche, Basel, Switzerland)]. Whole cell extracts of 5×105
cells were diluted in SDS-loading buffer and denatured for
5 min at 95 °C. The samples were then separated by
12.5 % SDS-polyacrylamide gel electrophoresis and blot-
ted onto a 0.2 μm PDV membrane (Bio-Rad Laboratories
Inc., Hercules, USA). After blocking in TBST 3 % BSA,
blots were incubated with IGF-IRβ antibody (C-20, Santa
Cruz Biotechnology, Dallas, USA) following by anti-
rabbit-HRP (Santa Cruz Biotechnology, Dallas, USA) and
developed with an ECL system (Western Lightning Plus
ECL; PerkinElmer, Waltham, USA). As loading control,
blots were stripped and incubated again with an anti-beta-
actin antibody-HRP (Abcam, Cambridge, UK).
Gene expression profiles
IGF1-R-associated GEP of an independent set of 86 adult
T-ALL samples were generated from raw data obtained
from the Microarrays Innovations in Leukemia (MILE)
multicenter study (HG-U133 Plus 2.0 and HG-U133
A+B; Affymetrix, Santa Clara, CA, USA) [24]. All pa-
tients had given written informed consent to partici-
pate according to the Declaration of Helsinki and the
MILE study design was approved by the ethics com-
mittees of the participating institutions [24]. As we
have used this already existent dataset and the experi-
ments we performed ourselves only included established
cell lines, no additional approval by an ethics committee
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was necessary. Information about the MILE study is pro-
vided in the cited article [24].
For analysis the samples were divided into a low
IGF1-R expression group (n = 42) and a high IGF1-R
group (n = 41) according to the expression level of
IGF1-R (represented by the median of the two probe
sets 203628_at, 203627_at). In order to obtain gene ex-
pression signatures that discriminated between high
and low IGF1-R expressers, samples in the high IGF1-R
expression group were compared to samples in the low
expression group. Genes were considered to be differ-
entially expressed if their expression showed at least a
1.5-fold change and a FDR < 0.05. The data analyses
were carried out with Partek Genomic Suite 6.6 (Partek
Incorporated, St. Louis). For further analysis DAVID
Bioinformatics Database was utilized to functionally an-
notate the genes up- or down-regulated in IGF1R-high
patients (Gene Ontology: GOTERM_BP_FAT).
Statistics
The statistical difference between values of two independ-
ent groups was tested using the nonparametric Mann–
Whitney U-test. For paired values the non-parametric
Wilcoxon matched-pair test was used. A P-value ≤ 0.05
(two-sided) was considered to indicate a significant differ-
ence. Statistical analyses were performed with Prism 5
software (GraphPad Software Inc., San Diego, USA).
Results
IGFBP7 over-expression sustains proliferation of Jurkat
cells
In order to determine the effect of IGFBP7 over-expression
in TALL, IGFBP7 was successfully over-expressed in Jurkat
and in Molt-4 cells (mean mRNA level IGFBP7-expression
increase: Jurkat 2643-fold, Molt-4 2273-fold; Fig. 1a and b;
P-value = 0.008). Secreted IGFBP7 was detected in the
conditioned medium of Jurkat and Molt-4 clones with
a stably integrated pcDNA3.1-IGFBP7 construct (re-
ferred to as pIGFBP7) (Fig. 1c). The secreted IGFBP7
protein concentration in the medium was increased
6.5-fold in Jurkat and 19.1-fold in Molt-4 cells as deter-
mined by ELISA.
To assess the effect of IGFBP7 over-expression, pCntrl
and pIGFBP7 transfected cells were grown for four days
at a high cell concentration without medium exchange
to promote starvation-induced apoptosis. The Jurkat
pCntrl transfected cells initially showed a steep increase
followed by a steep decrease of proliferation over the
time course of four days. In contrast the pIGFBP7
transfected cells showed a more shallow increase of
proliferation, which then remained at a constant level
throughout the experiment (Fig. 2a). The difference of
resistance against starvation-induced cell death was
highly significant with pIGFBP7 transfected Jurkat cells
showing 85 % more proliferation measured by WST-1
signal on day four compared to the pCntrl cells (P-
value = 0.0006; Fig. 2b). The Molt-4 cells showed a
somehow similar difference in the proliferation dynam-
ics of pCntrl and pIGFBP7 transfected cells, but was
not statistically significant (Fig. 2a).
Fig. 1 IGFBP7 expression in Jurkat and Molt-4 transfected for over-
expression. Jurkat and Molt-4 cells were transfected with pCntrl or
pIGFBP7 and cloned for 35 days in the presence of G418. a: IGFBP7
or GAPDH mRNA levels were assessed after additional 24 h culture
without G418 by RT-PCR. KG-1a served as control for constitutive
IGFBP7 mRNA expression. Images representative for four independent
experiments show PCR products separated by agarose gel electrophoresis.
b: IGFBP7 mRNA expression was measured by Sybr Green qRT-PCR and
normalized to GAPDH as housekeeping control. Mean values ± SEM of five
duplicate determinations. **P-value ≤ 0.01 (Mann–Whitney-U test)
c: Secreted IGFBP7 protein from Jurkat or Molt-4 clones was
quantified from the supernatants by ELISA after four days of culture
without G418. Mean values ± SEM of three triplicate determinations
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IGFBP7 over-expression induces G0/G1 arrest in T-ALL
cells
The effect of IGFBP7 over-expression on cell cycle dy-
namics in Jurkat and Molt-4 cells was measured with a
BrDU assay. Both cell lines showed a significant change
in cell cycle phases in pIGFBP7 compared to pCntrl cells
(Fig. 3a and b). Jurkat pIGFBP7 cells had significantly
more cells arrested in G0/G1 than pCntrl transfected
cells (mean % of total cells: 59.0 vs. 51.2, P-value =
0.0005) and less in G2/M-phase (mean % of total cells:
11.1 vs. 21.0, P-value = 0.0005). IGFBP7-over-expressing
Jurkat cells showed a higher percentage of cells in S-
phase (mean % of total cells: 22.8 vs. 16.5, P-value =
0.005) and lower percentage of cells were apoptotic
(mean % of total cells: 5.3 vs. 8.8, P-value = 0.002; Fig. 3a).
Likewise, Molt-4 pIGFBP7 transfected cells were signifi-
cantly more in G0/G1 arrest as compared to pCntrl
transfected cells (mean % of total cells: 46.0 vs. 40.1,
P-value = 0.001). IGFBP7-overexpressing Molt-4 cells were
also slightly less in G2/M-phase (mean % of total cells: 2.1
vs. 3.8; P-value = 0.02) and less apoptotic (mean % of total
cells: 4.4 vs. 7.5, P-value = 0.005) but did not show change
in S-phase compared to controls, respectively.
IGFBP7 induces resistance to chemotherapeutic drugs in
Jurkat cells
To test whether IGFBP7 over-expression influences the
sensitivity of T-ALL cells to cytostatic drugs used in
current ALL chemotherapy protocols, cells were incu-
bated with vincristine, etoposide, or asparaginase for
24 h and proliferation was assessed. Jurkat pIGFBP7
transfected cells remained significantly more prolifera-
tive compared to pCntrl transfected cells when treated
with vincristine (% of proliferation compared to un-
treated control: 65 vs. 22, P-value = 0.03) or asparaginase
(% of proliferation compared to untreated control: 122
Fig. 2 Proliferation of Jurkat clones over-expressing IGFBP7. Proliferation of Jurkat and Molt-4 clones transfected with pCntrl or pIGFBP7 was measured
in a WST-1 assay. a: Five independent experiments over a time course of four days. Mean values ± SD of triplicate determinations. **P-value≤ 0.01
(Mann–Whitney-U test) b: Proliferation at day four of culture of Jurkat cells. Mean values of 7 independent experiments done in triplicates are plotted;
lines indicate mean values ± SEM. ***P-value≤ 0.001 (Mann–Whitney-U test)
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Fig. 3 Cell cycle distribution of Jurkat and Molt-4 clones over-expressing IGFBP7. Clones transfected with pCntrl or pIGFBP7 were cultured for one
(Molt-4) or three days (Jurkat). Cell cycle states were analyzed by flow cytometry after BrdU incorporation and subsequent antibody binding in
combination with direct 7-AAD staining. a: Representative dot blots of transfected Jurkat cells show the gated populations: BrdU+ cells (upper
region) were considered to be in S-phase; BrdU−7-AADhigh (lower right region) in G2/M, BrdU−7-AADlow in G1/G0 (lower middle region) and
BrdU−7-AAD− apoptotic (lower left region). Percentages of cells within each region are indicated. b: Relative distribution of Jurkat and Molt-4 cells
in cell cycle phases. Triplicates of four independent experiments are plotted; lines indicate mean values ± SEM; *P-value≤ 0.05, **P-value≤ 0.01,
***P-value≤ 0.001 (Wilcoxon signed-rank test)
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vs. 77, P-value = 0.03; Fig. 4a). No significant differ-
ence in proliferation between pCntrl and pIGFBP7
transfected Jurkat clones was measured after treat-
ment with etoposide.
When cells in the same experimental setup were
stained for early and late apoptosis markers AnnexinV
and 7-AAD, a similar effect was measured: while 34.1 %
pCntrl transfected cells were on average apoptotic
(double positive for AnnexinV/7-ADD) after treated
with vincristine, only 14.6 % of IGFBP7-overexpressing
cells stained positive for AnnexinV/7-ADD (n = 4, P =
0.03; Fig. 4c). Treatment with asparaginase induced
Fig. 4 Cytostatic-drug treatment of a Jurkat clone overexpressing IGFBP7. Jurkat clones transfected with pCntrl or pIGFBP7 were incubated in the
presence of vincristine, etoposide or asparaginase for 24 hours. a: A WST-1 assay was performed and proliferation upon cytostatic drug-treatment
determined in relation to the respective untreated control (1). Mean values ± SEM of 4 independent experiments done in triplicates. *P-value≤
0.05 (Mann–Whitney-U-test) b: Cells stained with AnnexinV-FITC and 7-AAD were analyzed by flow cytometry. Representative dot plots out of four
independent experiments. Percentages of cells within each quadrant are indicated. c: Early apoptotic (AnnexinV+7-AAD−) as well as late apoptotic
and necrotic cells (AnnexinV+7-AAD+) were assessed as shown (b). Mean values ± SEM/SD of 4 independent experiments done in triplicates. *P-value≤
0.05 (Mann–Whitney-U test)
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apoptosis in 21.6 % of pCntrl transfected cells and only
9.9 % of pIGFBP7 Jurkat cells (n = 4, P-value = 0.03). No
significant effects of IGFBP7-overexpression on apop-
tosis were observed after treatment with etoposide or
cytarabine.
IGFBP7 over-expression induces reduction of IGF1-R
protein in Jurkat cells
IGF1-R surface expression was measured by flow cyto-
metric staining in pIGFBP7 compared to pCntrl trans-
fected Jurkat and Molt-4 clones. IGFBP7 over-expressing
Jurkat cells showed a significantly lower level of IGF1R
surface expression compared to control cells (Fig. 5a
and b; 68.4 % less compared to control, P-value = 0.002).
Molt-4 cells showed only a very low level of IGF1-R
expression, which was not influenced by IGFBP7 over-
expression (not shown). When whole cell lysates were an-
alyzed for IGF1-R expression by western blot, in Jurkat
pCntrl transfected IGF1-R was detected at 95 kDa, while
Jurkat pIGFBP7 transfected cells did not express a detect-
able amount of IGF1R, underscoring the flow cytometric
results. Molt-4 cells also showed no detectable protein
expression of IGF1-R (Fig. 5c). When IGF1-R mRNA
expression was determined by qRT-PCR, no significant
difference was found for pCntrl or pIGFBP7 transfected
cells (not shown). Thus, IGFBP7 over-expression resulted
in post-transcriptional reduction of IGF1-R protein abun-
dance in Jurkat cells.
IGFBP7-induced resistance is overcome by IGF1R
inhibition in Jurkat cells
Since IGFBP7 over-expression modulated IGF1-R pro-
tein abundance, we combined the treatment of chemo-
therapeutic drugs with an IGF1-R inhibitor to test
whether the IGFBP7-induced chemotherapy resistance
could be modulated by combination with an IGF1-R in-
hibitor. Jurkat pIGFBP7 transfected cells were more sen-
sitive to the exposure of the IGF1-R inhibitor AEW541
Fig. 5 IGF1-R protein in Jurkat and Molt-4 clones over-expressing IGFBP7. a: Jurkat clones transfected with pCntrl or pIGFBP7 were incubated for
four days without medium exchange. Cells were analyzed by flow cytometry for IGF1-R in viable cells according to their forward and side scatter
properties. Representative dot plots show each clone with a respective isotype-matched negative control (light grey) from an exemplary out of
five experiments. b: Results from five independent IGF-1R median fluorescence intensity (MFI) determinations in duplicates, lines indicate means
and SEM. **P-value≤ 0.01 (Mann–Whitney-U test) c: Jurkat or Molt-4 clones were cultured for one day and lysates subjected to Western-blot
analysis for IGF1-Rβ and β-actin. The cell line HeLa served as positive control. The Image is representative for three independent experiments
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than control clones (mean % of apoptotic cells: 64.2 vs.
41.5, P-value = 0.03). Combination of vincristine with
AEW541 reversed the resistance-inducing effect of
IGFBP7: Jurkat cells over expressing IGFBP7 regained
sensitivity to vincristine with 79.8 % of pIGFBP7 trans-
fected being apoptotic when treated in combination with
AEW541 compared to only 14.6 % when treated with
vincristine alone (P-value = 0.03). pCntrl-transfected Jur-
kat cells were less sensitive compared to pIGFBP7-
transfected cells to the combination treatment (mean %
of apoptotic cells: 51.9 vs. 79.8 %; P-value = 0.03).
In contrast, pIGFBP7 transfected Jurkat cells remained
significantly less sensitive to asparaginase when treated
in combination with AEW541 (mean % of apoptotic
cells: 14.5 vs. 40.8, P-value = 0.03; Fig. 6).
IGF1-R associated gene expression profiles of T-ALL
patients
To further explore the relevance of IGF1-R signaling in
primary T-ALL samples, we analyzed gene expression
data from 86 T-ALL patients for IGF1-R co-regulated
genes. In patient samples highly expressing IGF1-R 257
probe sets were differentially expressed. They corre-
sponded to 226 unique genes, hypothetical genes, pro-
teins and open reading frames. Of those 165 genes were
up-regulated and 61 down-regulated. For a complete list
of differentially expressed probe sets see Additional file 1:
Table S1 and Table S2.
In Gene Ontology analyses, genes highly expressed
and co-regulated with IGF1-R were significantly en-
riched in categories related to apoptosis (“anti-apoptosis”,
P-value = 0.01; “negative regulation of cell death”, P-value =
0.01; “negative regulation of programmed cell death”,
P-value = 0.01). The differentially expressed genes in
these categories included the anti-apoptotic gene BCL2,
genes related to chemo-resistance like ANXA4 and PRKCI,
as well as pro-apoptotic tumor suppressor genes TP53
and DAPK1 [25–29]. Interestingly, also genes involved
in leukemogenesis like NOTCH1 and HELLS, suggest-
ing a role of IGF1-R signaling not only in maintenance,
but also in initial transformation of leukemic blasts
(Table 1) [30, 31].
Differentially down-regulated genes in IGF1-R-high
T-ALL patients were enriched in the categories induc-
tion of apoptosis (P-value = 0.02) and induction of
programmed cell death (P-value = 0.02), the most func-
tionally established being pro-apoptotic gene BCL2L11
(Table 2).
Discussion
High expression of IGFBP7 was found to be associated
with poor survival and predicted primary therapy resist-
ance in T-ALL patients, while treatment of leukemic cells
lines with recombinant protein reduced proliferation [15].
Here we investigated the functional role of IGFBP7 in
acute leukemia and its possible mode of action.
In the T-ALL cell line Jurkat, pIGFBP7 transfection re-
sulted in a prolonged viability of cells in a starvation en-
vironment. Cell cycle analysis displayed a significant
change in the cell cycle distribution in response to
IGFBP7 over-expression in both Jurkat and Molt-4 cells:
significantly more cells were in G0/G1-phase and less
Fig. 6 Apoptosis in Jurkat clone over-expressing IGFBP7 upon treatment with cytostatic drugs in combination with IGF1-R inhibition. Jurkat clones
transfected with pCntrl or pIGFBP7 were incubated for one day with different drugs in combination with 500 nM IGF1-R-inhibitor AEW541. Cells
stained with AnnexinV and 7‑AAD were assessed by flow cytometry. Mean values ± SEM of 4 independent experiments done in triplicates; *P-
value≤ 0.05 (Mann-Whitney-U test)
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apoptotic or in G2/M-phase. In Jurkat cells also more
IGFBP7-overexpressing cells were in S-phase.
Extended G0/G1 arrest is one way of evading toxicity
of cytostatic drugs, since their mode of action is by dis-
turbing cell division [32]. When treated with vincristine,
a mitotic inhibitor, which binds to microtubulins during
metaphase, a significantly reduced proliferation and
apoptosis rate was seen for pIGFBP7 transfected Jurkat
cells. A previous study had found that IGFBP7 increased
asparagine synthase expression in ALL cells [21], pos-
sibly explaining the resistance of IGFBP7-overexpressing
Jurkat cells against asparaginase. Also for etoposide, a
slight but not significant resistance effect was seen, for
cytarabine it was even smaller. Since vincristine was the
only tested drug that is exclusively active in metaphase,
these results point to a cell cycle phase specificity of
IGFBP7-induced drug resistance. Since vincristine and
asparaginase are both routinely used in current chemo-
therapy regimens the results also provide an explanation
for the observed link between aberrantly high IGFBP7 ex-
pression and chemotherapy resistance in T-ALL patients.
A previous study had shown that IGFBP7 binds to the
extracellular domain of the IGF1-R [33]. In our setting
IGFBP7-overexpression resulted not only in a lower sur-
face abundance of the receptor but also lower total
IGF1-R protein expression. Since IGF1-R mRNA expres-
sion levels were not affected, IGFBP7 likely has a post-
transcriptional effect of on IGF1-R protein abundance.
When IGFBP7 over-expressing Jurkat cells were treated
with the IGF1-R inhibitor AEW541 in combination with
cytostatic drugs, the IGFBP7-induced resistance to vincris-
tine was overcome, but not the resistance against asparagi-
nase. Since the latter is not acting through cell cycle
inhibition, but through hydrolysis of asparagine, the re-
sults further underscore the mode of action of IGFBP7-
induced resistance by G0/G1 arrest through interaction
with IGF1-R.
Interestingly Molt-4, another T-ALL cell line, did not
show significant changes in proliferation in a starvation
environment and no significant resistance to cytostatic
drugs with respect to IGFBP7 over expression (data not
included). Cell cycle changes were also observed be-
tween pCntrl and pIGFBP7 transfected Molt-4 cells, but
to a lesser extent. Molt-4 cells natively express IGF1-R
at a very low level, which might account for the ob-
served reduced impact of IGFBP7 over-expression in
Molt-4 compared to Jurkat cells.
Intriguingly, a recent study on AML cell lines showed
different results to our findings in T-ALL [34]. Here,
several AML cell lines were less viable and more apop-
totic in serum-reduced medium after IGFBP7 over ex-
pression. The authors also showed a block at G2-phase
and a decrease in G0/G1-phase. Moreover the study
found no reduction of IGF1-R expression when IGFBP7
was over-expressed and most remarkably the utilized
AML cell lines were not resistant but sensitized for the
induction of cell death by chemotherapeutic drugs when
rIGFBP7 was added. This difference to our results in
T-ALL cell lines is likely due to highly tissue and disease
specific actions of IGFBP7, which will need to be further
investigated. It is also strikingly that the aforementioned
study showed a better prognosis of IGFBP7 high express-
ing AML patients, while in our ALL study cohort no such
associated had been observed [15].
IGF1-R inhibitors are a potential therapeutic option in
leukemia patients since in vitro IGF1-R inhibition re-
duced proliferation of leukemic cells [35–37]. So far,
clinical trials with various solid tumor patients unfortu-
nately showed only a few responders to small molecules
or antibodies targeting the IGF1-R [38]. In acute
leukemia patients, no studies with reagents exclusively
targeting IGF1-R have been conducted. However, our
analyses underscore the potential importance of IGF1-R
in T-ALL. The IGF1-R-associated GEP further underline
the biological relevance of IGF1-R in T-ALL pathogen-
esis as differentially up- and down-regulated genes were
enriched for several known players in leukemia such as
NOTCH1. Aberrant NOTCH1 signaling is a potent driver
of malignant T-cell transformation and it was previously
shown to up-regulate IGF1-R in T-ALL cells [39, 40].
Table 1 Probe sets over-expressed in high IGF1-R group which cluster in apoptosis-related Gene Ontology categories
GOTERM_BP_FAT
category
P-value Fold-enrichment Gene symbols
GO:0006916 Anti-apoptosis 0.01 3.83 ANXA4, STAMBP, DAPK1, BCL2, PRKCI, HELLS
GO:0043069 Negative regulation of programmed cell death 0.01 2.83 ANXA4, TP53, STAMBP, DAPK1, BCL2, PRKCI, NOTCH1, HELLS
GO:0060548 Negative regulation of cell death 0.01 2.82 ANXA4, TP53, STAMBP, DAPK1, BCL2, PRKCI, NOTCH1, HELLS
Table 2 Probe sets under-expressed in high IGF1-R group which cluster in apoptosis-related Gene Ontology categories
GOTERM_BP_FAT category P-value Fold-enrichment Gene symbols
GO:0006917 Induction of apoptosis 0.02 4.60 DDX20, BCL2L11, MAPK8, TNFSF8, ARHGEF7
GO:0006917 Induction of programmed cell death 0.02 4.58 DDX20, BCL2L11, MAPK8, TNFSF8, ARHGEF7
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Likewise, BCL-2 plays an important role in chemo-
resistance and pro-survival signaling and was shown to be
regulated by the IGF signaling cascade [41–43].
Conclusion
In summary, our results show that a combination of
chemotherapy with IGF1-R inhibition could improve
elimination of leukemic blasts in patients who are pos-
sibly more prone to chemotherapy resistance due to high
IGFBP7 expression and at the same time express IGF1-R
at a substantial level. It has been noted before that
IGF1-R inhibitor trials possibly lack the correct predict-
ive biomarkers to stratify patients that are more likely to
benefit of molecular directed therapies [38, 44]. IGFBP7,
in combination with IGF1-R expression, could serve as
such a marker.
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